Progressive pulmonary fibrosis: an expert group consensus statement

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Vincent Cottin reports an unrestricted grant to their institution from Boehringer Ingelheim; consulting fees from Boehringer Ingelheim, Roche, Galapagos, Galecto, Shionogi, Fibrogen, RedX Pharma and PureTech; payment or honoraria and support for attending meetings from Boehringer Ingelheim and Roche; and participation on a Data Safety Monitoring Board or Advisory Board for Roche/Promedior, Celgene/Bristol Myers Squibb and Galapagos, all in the 36 months prior to manuscript submission.

Conflict of interest: Raja Dhar reports external expert contracts from Cipla and Boehringer Ingelheim; speaker fees from the Indian Chest Society, Cipla and Boehringer Ingelheim; and support for attendance at a European Respiratory Society meeting from Cipla.

Conflict of interest: Sonye Danoff reports grant funding from Bristol Myers Squibb (Myositis ILD Trial), Boehringer Ingelheim (IN-BUILD and IN-BUILD-ON Trials) and Roche/Genentech (TRAIL Trial); royalties from UpToDate; Advisory Board fees from Boehringer Ingelheim and Lupin Pharma; payment for presentations from the France Foundation; funding for travel to present lectures from Boehringer Ingelheim; and participation on Data Safety Monitoring Boards for Galecto and Galapagos, all in the 36 months prior to manuscript submission; as well as a role as senior medical adviser and interim CMO for the Pulmonary Fibrosis Foundation and membership of the board of directors of the American Thoracic Society.

Conflict of interest: Kevin R. Flaherty reports research grants paid to their institution by Boehringer Ingelheim; and ILD consulting fees paid to them by Boehringer Ingelheim, Roche/Genentech, Blade Therapeutics, Shionogi, DevPro, AstraZeneca, Pure Health, Fibrogen, Sun Pharmaceuticals, Pliant, United Therapeutics, Arrowhead, Lupin, Polarean and PureTech, all in the 36 months prior to manuscript submission.

Conflict of interest: Kevin K. Brown reports lung fibrosis research grants from the National Heart, Lung and Blood Institute; being an external science advisor to AbbVie, CSL Behring, Dispersol, Huitai Biomedicine, Lilly, RedX Pharma, Theravance and Translate Bio; being a DMC chair for Biogen; Scientific Advisory Board membership for Blade Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, DevPro Biopharma, Galapagos NV, Galecto, Open Source Imaging Consortium, Pliant, Sanofi and Third Pole; DMC membership for Humanetics; and a scientific collaboration with Sekisui Medical Co, all in the 36 months prior to manuscript submission; as well as leadership or fiduciary roles for the Fleischner Society and Open Source Imaging Consortium.

Conflict of interest: Anant Mohan declares no competing interests.

Conflict of interest: Elizabeth Renzoni declares a research contract payment and Advisory Board meeting payment to their institution by Boehringer Ingelheim; lecture fees paid to their institution by Boehringer Ingelheim, Roche and Chiesi; and registration and travel expenses for the American Thoracic Society conference, paid by Boehringer Ingelheim, all in the 36 months prior to manuscript submission.

Conflict of interest: Murali Mohan reports no competing interests.

Conflict of interest: Zarir Udwadia reports no competing interests.

Conflict of interest: Padmanabha Shenoy reports no competing interests.

Conflict of interest: David Currow reports intellectual property payments and royalties from Mayne Pharma International Pty Ltd, a manufacturer of sustained-release morphine; and consulting fees from Helsinn Pharmaceuticals, in the 36 months prior to manuscript submission; as well as leadership or fiduciary roles for the Dust Diseases Board of New South Wales and the Board of the Cancer Institute NSW.

Conflict of interest: Anand Devraj reports consulting fees from Boehringer Ingelheim, Roche, Galecto, Galapagos, Brainomix and Vicore, all in the 36 months prior to manuscript submission.

Conflict of interest: Bhavin Jankharia reports payment or honoraria to their institution from Cipla India, Lupin India, Boehringer Ingelheim and German Remedies India, all in the 36 months prior to manuscript submission; as well as being a past president of the Indian Musculoskeletal Society and the Indian Radiology and Imaging Association.

Conflict of interest: Ritu Kulshrestha reports no competing interests.

Conflict of interest: Steve Jones reports grants to their institution from Boehringer Ingelheim, Trevi for being Chair of Action for Pulmonary Fibrosis (APF) and President of the European Pulmonary Fibrosis Federation (EU-IPFF). Both these organisations implement projects in partnership with industry. I am not involved in these projects and do not gain personally; reports payment or honoraria from Boehringer Ingelheim, Vicore, Roche to their institution; and participation on a Data Safety Monitoring Board or Advisory Board as Galecto DSMB for an anti-fibrotic therapy in the 36 months prior to manuscript submission.

Conflict of interest: Claudia Ravaglia reports no competing interests.

Conflict of interest: Silvia Quadrelli reports speaker fees from Boehringer Ingelheim in the 36 months prior to manuscript submission.

Conflict of interest: Rajam Iyer reports no competing interests.

Conflict of interest: Sahajal Dhooria reports no competing interests.

Conflict of interest: Martin Kolb reports research funding for preclinical work from Boehringer Ingelheim and Pieris; research funding for a clinical project from Roche; consulting fees from Boehringer Ingelheim, Roche, Horizon, Cipla, AbbVie, Belerophon, Algernon, CSL Behring, United Therapeutics and AstraZeneca; payment or honoraria from Novartis, Boehringer Ingelheim and Roche; payment for court testimony from Roche; participation on a Data Safety Monitoring Board or Advisory Board for Covance and United Therapeutics; and an allowance paid to their institution from the European Respiratory Society relating to their duties as European Respiratory Journal Chief Editor, all in the 36 months prior to manuscript submission.

Conflict of interest: Athol Wells reports payments or honoraria from Boehringer Ingelheim and Roche; and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, Roche and Veracyte, all in the 36 months prior to manuscript submission.

Conflict of interest: Sujeet K. Rajan reports grants to their institution, consulting fees and lecture fees from Cipla and Boehringer Ingelheim; speaker fees from the Indian Chest Society; and support from Cipla to attend European Respiratory Society meeting, all in the 36 months prior to manuscript submission.